The World Health Organization will temporarily suspend enrollment in hydroxychloroquine trials in a study of four treatment options for COVID-19, the WHO announced Monday in a press conference. Mary Meisenzahl writes in Business Insider that  the drug is part of the “Solidarity” international clinical trial sponsored by the WHO in 17 countries, with others expressing interest. Chief Scientist Dr. Soumya Swaminathan explained that the trial is overseen by a board of experts and an independent data safety monitor. The steering committee met over the weekend and decided in light of uncertainty about the drug, that they should “err on the side of caution and suspend enrollment into the hydroxychloroquine arm” of the trial, Dr. Swaminathan said.